Current Treatment Options in Neurology

, Volume 3, Issue 2, pp 181–188

Medication overuse headache

  • William B. Young

Opinion statement

  • •Medication overuse headache is common and affects 2% of the United States population.

  • •Simple analgesics, caffeine-containing analgesics, butalbital-containing analgesics, opioids, ergotamine, and triptans may cause medication overuse headache. The recidivism rate is higher after detoxification from butalbital and opioids than after detoxification from other substances.

  • •Treatment venues have included the patient’s home, an infusion center, or a hospital setting. No consensus exists to determine the setting that is most appropriate.

  • •Patients with analgesic overuse headache have a different psychologic substrate than psychiatric substance abusers. Most should not be treated in psychiatric detoxification facilities, although, psychiatric assessment and support may be beneficial.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Saper J: Daily chronic headache. Neurol Clin 1990, 8:891–301.PubMedGoogle Scholar
  2. 2.
    Mathew NT: Drug induced headache. Neurol Clin 1990, 8:903–912.PubMedGoogle Scholar
  3. 3.
    Saper JR: Chronic headache syndromes. Neurol Clin 1989, 7:387–412.PubMedGoogle Scholar
  4. 4.
    Saper JR: Ergotamine dependency: a review. Headache 1987, 27:435–438.PubMedCrossRefGoogle Scholar
  5. 5.
    Saper JR, Jones JM: Ergotamine tartrate dependency: features and possible mechanisms. Clin Neuropharmacol 1986, 9:244–256.PubMedCrossRefGoogle Scholar
  6. 6.
    Andersson PG: Ergotism: the clinical picture. In Drug Induced Headache. Edited by Diener HC, Wilkinson MS. Berlin: Springer-Verlag; 1988:16–19.Google Scholar
  7. 7.
    Rapoport AM, Weeks RE, Sheftell FD, Baskin SM, Verdi J: The "analgesic washout period": a critical variable evaluation in the evaluation of headache treatment efficacy. Neurology 1986, 36:100–101.Google Scholar
  8. 8.
    Baumgartner C, Wessly P, Bingol C, et al.: Long-term prognosis of analgesic withdrawal in patients with drug-induced headaches. Headache 1989, 29:510–514.PubMedCrossRefGoogle Scholar
  9. 9.
    Mathew NT, Reuveni U, Perez F: Transformed or evolutive migraine. Headache 1987, 27:102–106.PubMedCrossRefGoogle Scholar
  10. 10.
    Kudrow L: Paradoxical effects of frequent analgesic use. Adv Neurol 1982, 33:335–341.PubMedGoogle Scholar
  11. 11.
    Rapoport AM: Analgesic rebound headache. Headache 1988, 28:662–665.PubMedCrossRefGoogle Scholar
  12. 12.
    Diener HC, Dichgans J, Scholz E, et al.: Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989, 236:9–14.PubMedCrossRefGoogle Scholar
  13. 13.
    Rasmussen BK, Jensen R, Olesen J: Impact of headache on sickness absence and utilization of medical services. J Epidemiol Community Health 1992, 46:443–446.PubMedCrossRefGoogle Scholar
  14. 14.
    Silverman K, Evans SM, Strain EC, Griffiths RR: Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992, 327:1109–1114.PubMedCrossRefGoogle Scholar
  15. 15.
    Dichgans J, Diener HD, Gerber WD, et al.: Analgetikainduzierter dauerkopfschmerz. Dtsch Med Wochenschr 1984, 109:369.PubMedGoogle Scholar
  16. 16.
    Solomon S, Lipton RB, Newman LC: Clinical features of chronic daily headache. Headache 1992, 32:325–329.PubMedCrossRefGoogle Scholar
  17. 17.
    Diener HC, Tfelt-Hansen P: Headache associated with chronic use of substances. In The Headaches. Edited by Olesen J, Tfelt-Hansen P, Welch KMA. New York: Raven Press; 1993:721–727.Google Scholar
  18. 18.
    Kaiser RS: Substance abuse and headache. Paper presented at: 41st Annual Scientific Meeting; 1999; Boston, MA.Google Scholar
  19. 19.
    Warner JS: Time required for improvement of an analgesic rebound headache. Headache 1998, 38:229–230.PubMedCrossRefGoogle Scholar
  20. 20.
    SilbersteinSD, Lipton RB, Sliwinski M: Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996, 47:871–875. This paper proposes the classification system that has current widespread acceptance in the United States.PubMedGoogle Scholar
  21. 21.
    Silberstein SD: Chronic daily headache and tensiontype headache. Neurology 1993, 43:1644–1649.PubMedGoogle Scholar
  22. 22.
    Wilkinson M: Introduction. In Drug Induced Headache. Edited by Diener HC, Wilkinson M. Berlin: Springer-Verlag; 1988:1–2.Google Scholar
  23. 23.
    Scholz E, Diener HC, Geiselhart S, Wilkinson M: Drug-induced headache: does a critical dosage exist? In Drug Induced Headache. Edited by Diener HC, Wilkinson M. Berlin: Springer-Verlag; 1988:29–43.Google Scholar
  24. 24.
    Katsarava Z, Fritsche G, Diener HC, Limmroth V: Drug-induced headache (DIH): following the use of different triptans [abstract]. Cephalalgia 2000, 20:293.Google Scholar
  25. 25.
    Raskin NH: Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986, 36:995–997.PubMedGoogle Scholar
  26. 26.
    Silberstein SD, Schulman EA, Hopkins MM: Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990, 30:334–339.PubMedCrossRefGoogle Scholar
  27. 27.
    Diener HC, Gerber WD, Geiselhart S: Short and long-term effects of withdrawal therapy in drug-induced headache. In Drug Induced Headache. Edited by Diener HC, Wilkinson M. Berlin: Springer-Verlag; 1988:133–142.Google Scholar
  28. 28.
    Hering R, Steiner TJ: Abrupt outpatient withdrawal from medication in analgesic-abusing migraineurs. Lancet 1991, 337:1442–1443.PubMedCrossRefGoogle Scholar
  29. 29.
    SilbersteinSD, Rosenberg J: Multispecialty consensus on diagnosis and treatment of headache. Neurology 2000, 54:1553. Evidence-based consensus that is the result of 5 years’ work across many specialty associations. The results of a metaanalysis for the treatment of migraine are presented in a useful format.PubMedGoogle Scholar
  30. 30.
    Krymchantowski AV, Barbosa JS: Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia 2000, 20:107–113.PubMedCrossRefGoogle Scholar
  31. 31.
    Smith TR: Low dose tizanidine combined with long-acting NSAIDs for detoxification from analgesic rebound headache: a retrospective review. Cephalalgia 2000, 20:381.CrossRefGoogle Scholar
  32. 32.
    Silberstein SD, Saper JR: Migraine: Diagnosis and treatment. In Wolff’s Headache and Other Head Pain, edn 6. Edited by Dalessio DJ, Silberstein SD. New York: Oxford University Press; 1993:96–170.Google Scholar
  33. 33.
    Silberstein SD, Young WB: Safety and efficacy of ergotamine tartrate and DHE in the treatment of migraine and status migrainosus: for the working panel of the headache and facial pain section of the American Academy of Neurology. Neurology 1995, 45:577–584.PubMedGoogle Scholar
  34. 34.
    Mathew NT, Kailasam J: Repetitive intravenous administration of valproate sodium in intractable migraine: comparison with intravenous dihydroergotamine (DHE) [abstract]. Neurology 2000, 54:A22.Google Scholar
  35. 35.
    Krusz JC, Scott V, Belanger J: Intravenous propofol: unique effectiveness in treating intractable migraine. Headache 2000, 40:224–230. cribes unusual headache treatment being used in conjunction with detoxification in some centers for analgesic-induced headache.PubMedCrossRefGoogle Scholar
  36. 36.
    Wang SJ, Silberstein SD, Young WB: Droperidol treatment of status migrainosus and refractory migraine. Headache 1997, 37:377–382.PubMedCrossRefGoogle Scholar
  37. 37.
    Linder SL: Treatment of acute childhood migraine headaches. Cephalalgia 1991, 11:120–121.Google Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • William B. Young
    • 1
  1. 1.Department of NeurologyThe Thomas Jefferson University Hospital, Jefferson Headache CenterPhiladelphiaUSA

Personalised recommendations